Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Early life body size, growth and risks of systemic lupus erythematosus - A large Danish observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians

    Research output: Contribution to journalLetterResearchpeer-review

  • Murray B Urowitz
  • Dafna D Gladman
  • Vernon Farewell
  • Jiandong Su
  • Juanita Romero-Diaz
  • Sang-Cheol Bae
  • Paul R Fortin
  • Jorge Sanchez-Guerrero
  • Ann Elaine Clarke
  • Sasha Bernatsky
  • Caroline Gordon
  • John G Hanly
  • Daniel J Wallace
  • David A Isenberg
  • Anisur Rahman
  • Joan T Merrill
  • Ellen Ginzler
  • Graciela S Alarcón
  • W Winn Chatham
  • Michelle A Petri
  • Ian N Bruce
  • Munther A Khamashta
  • Cynthia Aranow
  • Mary Anne Dooley
  • Susan Manzi
  • Rosalind Ramsey-Goldman
  • Ola Nived
  • Andreas Jönsen
  • Kristján Steinsson
  • Asad A Zoma
  • Guillermo Ruiz-Irastorza
  • S Sam Lim
  • Kenneth C Kalunian
  • Murat Ỉnanç
  • Ronald van Vollenhoven
  • Manuel Ramos-Casals
  • Diane L Kamen
  • Soren Jacobsen
  • Christine A Peschken
  • Anca Askanase
  • Thomas Stoll
View graph of relations

Objective: In previous studies, atherosclerotic vascular events (AVEs) were shown to occur in ~10% of patients with systemic lupus erythematosus (SLE). We undertook this study to investigate the annual occurrence and potential risk factors for AVEs in a multinational, multiethnic inception cohort of patients with SLE. Methods: A large 33-center cohort of SLE patients was followed up yearly between 1999 and 2017. AVEs were attributed to atherosclerosis based on SLE being inactive at the time of the AVE as well as typical atherosclerotic changes observed on imaging or pathology reports and/or evidence of atherosclerosis elsewhere. Analyses included descriptive statistics, rate of AVEs per 1,000 patient-years, and univariable and multivariable relative risk regression models. Results: Of the 1,848 patients enrolled in the cohort, 1,710 had ≥1 follow-up visit after enrollment, for a total of 13,666 patient-years. Of these 1,710 patients, 3.6% had ≥1 AVEs attributed to atherosclerosis, for an event rate of 4.6 per 1,000 patient-years. In multivariable analyses, lower AVE rates were associated with antimalarial treatment (hazard ratio [HR] 0.54 [95% confidence interval (95% CI) 0.32–0.91]), while higher AVE rates were associated with any prior vascular event (HR 4.00 [95% CI 1.55–10.30]) and a body mass index of >40 kg/m 2 (HR 2.74 [95% CI 1.04–7.18]). A prior AVE increased the risk of subsequent AVEs (HR 5.42 [95% CI 3.17–9.27], P < 0.001). Conclusion: The prevalence of AVEs and the rate of AVE accrual demonstrated in the present study is much lower than that seen in previously published data. This may be related to better control of both the disease activity and classic risk factors.

Original languageEnglish
JournalArthritis and Rheumatology
Issue number10
Pages (from-to)1734-1740
Number of pages7
Publication statusPublished - Oct 2020

    Research areas

  • Adult, Atherosclerosis/epidemiology, Comorbidity, Female, Humans, Incidence, Lupus Erythematosus, Systemic/epidemiology, Male, Middle Aged, Prevalence, Risk, Young Adult

ID: 61876165